Navigation Links
Preclinical study finds drug helps against pancreatic cancer
Date:10/24/2013

October 23, 2013(BRONX, NY)An investigational drug that disrupts tumor blood vessels shows promise against a rare type of pancreatic cancer, scientists at Albert Einstein College of Medicine of Yeshiva University have found. Their results were presented October 20 during a poster session at an international cancer conference.

The drug Zybrestat selectively targets and collapses tumor blood vessels, depriving the tumor of oxygen and making its cells die. In experiments involving a mouse model of pancreatic neuroendocrine tumors, Einstein scientists found that infusing mice with Zybrestat three times per week for four weeks resulted in significant antitumor activity compared with control mice given a placebo.

The findings were presented in Boston at the American Association for Cancer Research-National Cancer Institute-European Organisation for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics. Presenting for Einstein was ZiQiang Yuan, M.D., research assistant professor of surgery at Einstein. The senior author is Steven K. Libutti, M.D., professor of genetics at Einstein and professor and vice chair of surgery at Einstein and Montefiore Medical Center, the University Hospital and academic medical center for Einstein.

Pancreatic cancer is the fourth-leading cause of cancer death in the U.S. According to the National Cancer Institute, more than 45,000 Americans will be diagnosed with pancreatic cancer in 2013 and more than 38,000 will die of the disease. Exocrine pancreatic cancer, the more common and usually fatal type
'/>"/>

Contact: Deirdre Branley
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Preclinical data support ongoing clinical trials testing IDO inhibitors as a treatment for cancer
2. Genetically-engineered preclinical models predict pharmacodynamic response
3. Preclinical study identifies master proto-oncogene that regulates ovarian cancer metastasis
4. Preclinical tests shows agent stops slippery proteins from binding, causing Ewing sarcoma
5. Mayo Clinic: Preclinical tests may lead to new approach to treat CNS lymphoma
6. Study Suggests Vaccine May Help Kids With Brain Cancer
7. Study reveals how cancer drug causes diabetic-like state
8. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
9. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
10. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
11. No Added Cancer Risk From Hip Replacement Materials: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... with less intensive (and expensive) practice patterns appear to ... patients unnecessary and excessive medical care, according to a ... "Growing concern about the costs and harms of medical ... avoid the provision of unnecessary care," said lead author ... Dartmouth Institute for Health Policy & Clinical Practice. ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Evolve ... within the primary and urgent care arena, is ... opening coincides with a health fair the clinic ... incorporating technology to assist patients in achieving high ... Medical Clinics’ pricing structure is a groundbreaking change ...
(Date:9/2/2014)... 2014 The first trial involving ... implant ( http://www.depuypinnacle-lawsuit.com/depuy-pinnacle-hip-implant/ ) will soon get underway, ... District Court, Northern District of Texas, Bernstein Liebhard ... Johnson and its DePuy Orthopaedics unit are facing ... caused recipients to suffer serious and debilitating complications. ...
(Date:9/2/2014)... 02, 2014 The exclusive ClinicCRM patient ... designed to help doctors manage foreign patient flow, enable ... conversion rates and clink revenue. Since its launch in ... in sales revenue and a 70 percent increase in ... their own healthcare practices. , With its ease of ...
(Date:9/2/2014)... California, San Diego School of Medicine have identified an ... The findings, reported in the current issue of PNAS, ... mortality worldwide. An estimated 40,000 women in America will ... American Cancer Society. , "The take-home message of the ... target breast cancer metastasis through a pathway regulated by ...
Breaking Medicine News(10 mins):Health News:Residency training predicts physicians' ability to practice conservatively 2Health News:Evolve Medical Clinics Announces Grand Opening of Annapolis, Maryland Location 2Health News:Evolve Medical Clinics Announces Grand Opening of Annapolis, Maryland Location 3Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 4Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 2Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 3Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 4Health News:Enzyme controlling metastasis of breast cancer identified 2
... But researcher stresses risk is still low , , MONDAY, Jan. ... the risk of developing brain cancer at a young age ... people with malignant brain tumors and 238 people with no ... most common type of brain cancer. Patients survive an average ...
... heart disease to rest , , MONDAY, Jan. 26 (HealthDay News) ... in vegetable oils, nuts and seeds possibly being bad for ... American Heart Association claims. , "There has been a lot ... might be bad," said William S. Harris, the nutritionist heading ...
... of American Physicians, Inc. Chief Executive Officer James L. ... Spirit of Life(R) Award, City of Hope,s ... celebrating Mr. Weidner and his award will be held ... Saturday, November 14. Spirit of Life(R) Award honorees ...
... Buy is Exclusive Retail Partner WARREN, N.J., Jan. ... VM ) announced today that it is joining ... of the LG Pink Flare limited edition handset, ... (Photo: http://www.newscom.com/cgi-bin/prnh/20090126/NY62794 ) , (Logo: ...
... Nephros, Inc. (Pink Sheets: NEPH), a medical device company ... control, and water purification, today announced that its common ... the symbol "NEPH." The Company also announced that ... the NYSE Alternext US LLC (formerly, the American Stock ...
... people tend to overestimate the dangers, study finds, , , ... the minds of U.S. minorities and the disabled more ... , Ethnic minorities, as well as the disabled and ... changes based on terrorism fears, such as avoiding certain ...
Cached Medicine News:Health News:Omega-6 Fatty Acids Can Be Good for You 2Health News:Omega-6 Fatty Acids Can Be Good for You 3Health News:James L. Weidner Named 2009 Spirit of Life(R) Award Recipient by City of Hope 2Health News:Virgin Mobile USA Launches Limited Edition Pink Flare Handset to Benefit Susan G. Komen for the Cure(R) 2Health News:Virgin Mobile USA Launches Limited Edition Pink Flare Handset to Benefit Susan G. Komen for the Cure(R) 3Health News:Nephros Common Stock Now Quoted in Pink Sheets 2Health News:Nephros Common Stock Now Quoted in Pink Sheets 3Health News:Terror Fears Tougher on Minorities, Disabled 2Health News:Terror Fears Tougher on Minorities, Disabled 3
(Date:9/2/2014)... RALEIGH, N.C. and ,S-HERTOGENBOSCH, the ... Europe ( http://www.healthlinkeurope.com ) has expanded its North American ... 100% medical facility, providing warehousing, fulfillment and order to ... North America , utilizing our global ERP platform. ... since 1994 serving our customers in Europe ...
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire-iReach/ -- The Australian ... universal healthcare coverage and good access to facilities ... and its associated disease burden, well-defined regulatory guidelines, ... of a new manufacturing policy will drive the ... a focus on generic substitution and price cuts ...
(Date:9/2/2014)... 2014  Based on its recent analysis of ... & Sullivan recognizes Novian Health, Inc. with the ... Technology Innovation Leadership. Novian Health has greatly improved ... with its proprietary technology, Novilase ® Laser ... and easy-to-control ultrasound-guided thermo ablation device that performs ...
Breaking Medicine Technology:HealthLink Europe opens North American medical warehouse operation 2Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 2Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 3Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 4Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 5Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 2Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 3Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 4Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 5
... 15 GeoVax Labs, Inc. (OTC,Bulletin Board: GOVX), an ... and provided an,operational update for the quarter ended September ... September 30, 2007 The Company recorded a net ... 2007, compared to $283,434 for the same period in ...
... BRISBANE, Calif., Nov. 15 BiPar,Sciences, Inc., a ... announced it has initiated a Phase 2 study ... triple-negative breast,cancer that do not express the estrogen, ... the Phase 2 trial in this indication-which,represents a ...
Cached Medicine Technology:GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 2GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 3GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 4GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 5GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 6GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 7GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 8GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 9GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 10BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data 2BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data 3
... 400 System is an automated multiplexing platform ... SNP detection, pathogen sequence detection and pharmacogenetics ... be applied to an open and flexible ... be reused until all tests sites have ...
... venous pressure monitoring, blood sampling, and ... polyurethane PICC line sets offer:, , ... Micropuncture Introducer Needle, Biocompatible Polyurethane ... to patient specific anatomy. Remove catheter ...
Cable connections for 5 different adapters: Storz, ACMI, Pentax, Wolf and Olympus....
... epTIPS Filter have an integrated ... without "self-sealing" additives. This filter provides ... by aerosols, and it does not ... incorrect pipetting. Samples can then be ...
Medicine Products: